I review things for a living, or close enough to it, and the way I review things is I stop trusting the pitch the second someone tries to sell me a feeling. “You’ll feel twenty-five again.” Sure. So when a friend asked me whether TRT was worth it, I didn’t answer him with a vibe. I went and read the three studies that actually hold this whole industry up, cover to cover, over about a month. What follows is what I’d tell him over a beer: what the marketing claims, what I actually found in the data, where the treatment earns its keep, and where it doesn’t.
What the sales pitch claims
Walk into any testosterone clinic’s ad copy and you’ll hear some version of the same three promises: more energy, more muscle, your younger self back. The product underneath the pitch is usually an injectable ester, cypionate or enanthate, weekly or every other week, sometimes a gel or cream instead. Often it comes bundled with supporting drugs: HCG or gonadorelin to stop your testicles from shutting down (testosterone therapy suppresses natural production and fertility along with it), anastrozole if bloodwork shows estrogen creeping up, or enclomiphene and clomiphene for guys who’d rather nudge their own production up than replace it wholesale.
The thing I checked first, before I touched a single trial, was the eligibility bar. This is supposed to be treatment for hypogonadism, a documented deficiency confirmed by blood work, in a man who also has symptoms. It is not a supplement. It is not a Tuesday tune-up for a guy whose numbers are already fine. The Endocrine Society’s 2018 clinical practice guideline, the document doctors are actually supposed to follow, is unambiguous: you need symptoms and unequivocally low testosterone, confirmed on a repeat fasting morning blood draw, not one so-so number next to a checklist of tiredness [1]. Any clinic willing to prescribe off a quiz alone has already skipped step one. That single sentence told me more about which providers to trust than anything in their marketing copy.
My honest read of the evidence
I went into the biggest trial, the Testosterone Trials, expecting to find the energy claim on shaky ground. It’s worse than shaky. It’s not there. This is a placebo-controlled set of trials in 790 men aged 65 and older with low testosterone, published in the New England Journal of Medicine in 2016, and it’s the most rigorous look we have at what raising testosterone does in older men [2]. On the vitality measure, a standard fatigue scale, testosterone showed no significant benefit over placebo [2]. Read that twice. The exact claim clinics lead with, the one on the billboard, failed to show up in the best trial we have.
What did show up was real, just not what gets top billing in the ads. Sexual activity, sexual desire, and erectile function all improved significantly against placebo [2]. Mood improved, modestly. Physical function was a mixed bag, better on pooled walking-distance measures but not significant standing alone. So here’s my honest one-line summary: in men who actually qualify, testosterone reliably helps in the bedroom and gives a small lift to mood. The “feel young again” pitch is selling a result the data simply doesn’t back.
Then I went hunting for the scare story, because for years the heart was the open question mark on this whole treatment. TRAVERSE, published in the New England Journal of Medicine in 2023, was built specifically to settle it, enrolling 5,246 men aged 45 to 80 with hypogonadism who already had cardiovascular disease or were at high risk for it [3]. That’s the exact population doctors have worried about for decades, studied on purpose, at scale.
The headline number is genuinely reassuring: testosterone was noninferior to placebo for major adverse cardiac events, 7.0 percent versus 7.3 percent [3]. I went looking for the catch here and I’ll admit it, I didn’t fully find one at the top level. But I’m not going to stop reading at the headline, because the same trial flagged higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group [3]. Not reasons to refuse the treatment. Reasons a clinician should be watching your labs.
Where it holds up, and where it doesn’t
Everything else that came up in my reading fell into three buckets, and every single one of them resolved the same way: not “avoid this,” but “this needs a person watching it.”
Fertility: standard TRT suppresses your own production and can tank sperm count, which is exactly why real protocols carry HCG, gonadorelin, or SERMs like enclomiphene alongside it, and why fertility plans belong in the first appointment, not a panicked one six months in. Red blood cells: testosterone can raise hematocrit and thicken the blood, which is why the guideline puts hematocrit checks on the first-year monitoring list, full stop, not optional [1]. Estrogen and the prostate: testosterone partially converts to estradiol (hence anastrozole in some protocols), and the guideline builds a prostate-risk check into the monitoring schedule [1].
Line those three up and the pattern is obvious. Every real risk here is a manageable one, and the thing doing the managing is a clinician reading your bloodwork, not a vial that showed up in a padded envelope. That’s the moment my review stopped being about the molecule and started being about the delivery, because the molecule is identical no matter who sells it to you.
I’ll name one supervised option here since abstractions don’t help anyone: FormBlends runs a physician-supervised telehealth model, a licensed physician reviews your history and bloodwork, the testosterone and any supporting medications are compounded through a licensed 503A pharmacy, and monitoring is baked into the model rather than bolted on afterward. Their testosterone-cypionate page spells out the monitoring panel directly (total and free testosterone, estradiol, hematocrit, PSA, and a lipid profile) and lists roughly $30 to $100 a month for the most-prescribed form of TRT in the country. I’m flagging it the same way I flag anything in this piece, as a case worth examining, not a coupon code. Nothing here is for sale and there’s no checkout. What that oversight layer buys you, set against the “not for human use” vials that show up from outfits that vetted nothing about you and answer for nothing they shipped, is the entire safety margin this article has been circling.
The verdict
I went in braced to write a takedown. I came out with something less exciting and more useful. Testosterone replacement therapy is legitimate medicine for men with a documented, lab-confirmed deficiency. It reliably improves sexual function and gives mood a modest bump. It does not reliably fix your energy, no matter what the ad says, and it has no business being prescribed to a man whose levels are already in range. On the cardiovascular question, monitored men come out fine on the big endpoints, with specific side effects that monitoring exists to catch. My rating, if you want one: solid treatment, oversold pitch, and the whole difference between a good experience and a bad one comes down to whether someone with a medical license is actually looking at your labs.
Questions I kept getting asked
Does it actually give you more energy?
No, not reliably, and this was the single biggest surprise in my whole read-through. In the Testosterone Trials, treatment showed no significant benefit for vitality on a standard fatigue scale [2]. What it did move was sexual activity, desire, and erectile function, plus a modest mood bump. If your levels are genuinely low, expect help in those lanes more than an energy jolt. If your levels are normal, the evidence doesn’t support taking it to feel peppier.
Is it safe for the heart?
For monitored men with low testosterone, yes on the major endpoints. TRAVERSE found testosterone noninferior to placebo for major cardiac events, 7.0 percent versus 7.3 percent [3]. The same trial found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, which is exactly why ongoing labs and check-ins matter [3]. Not “risk-free.” Not “dangerous.” Managed.
Do I really need bloodwork first?
Yes, and I’d walk away from any provider who suggests otherwise. The Endocrine Society guideline requires symptoms plus unequivocally low testosterone confirmed on a repeat fasting morning draw before a diagnosis is even made [1]. Bloodwork is also how dosing gets set safely and how a rising hematocrit gets caught before it’s a problem. A prescription off a questionnaire alone skips the first step of real medicine.
Will this mess with my fertility?
It can. Standard TRT suppresses your own production and can lower sperm count. That’s manageable, which is exactly why a good protocol includes more than testosterone alone, things like HCG and gonadorelin to preserve testicular function, or enclomiphene and clomiphene to raise your own levels while protecting fertility. Say it out loud at the first appointment so the plan gets built around it from day one.
Does TRT cause prostate cancer?
Current evidence doesn’t back that up. The old “feeding the fire” theory that made the rounds decades ago hasn’t held up well, and the Testosterone Trials found no significant increase in prostate cancer rates among treated men. TRT can make existing prostate tissue grow, though, so men with an active or suspected prostate cancer diagnosis are usually excluded, and PSA monitoring stays part of the deal.
Does TRT cause hair loss?
It can speed it up if you were already genetically wired for male-pattern baldness. Testosterone converts to DHT, which shrinks susceptible follicles. If the men in your family kept their hair, your personal odds are better. If they didn’t, TRT may fast-forward something that was probably coming anyway. It doesn’t invent baldness out of nowhere in men without that genetic switch.
What does this actually cost, and will insurance touch it?
It varies a lot by form and source. Generic injectable cypionate at a retail pharmacy is often under fifty dollars a month. Gels, patches, and pellets cost more. Insurance is inconsistent and usually wants documented low levels and a specific diagnosis before it pays for anything. Some men skip that maze entirely and go through physician-supervised compounding pharmacies like FormBlends, where the pricing is upfront and a clinician is actually overseeing the prescription.
Who is this treatment actually for?
Men with confirmed low testosterone on at least two morning blood draws, plus real symptoms, low libido, fatigue, mood changes. It’s a targeted fix for a documented deficiency. It is not a performance shortcut and it is not an anti-aging product, whatever the ad copy implies, and it’s not intended for men whose levels are sitting in the normal range already.
References
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2018. Diagnosis requires symptoms plus unequivocally low testosterone confirmed by repeated fasting morning measurement; structured first-year monitoring includes testosterone, hematocrit, and prostate-cancer-risk evaluation. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Snyder PJ, et al. Effects of Testosterone Treatment in Older Men (The Testosterone Trials). New England Journal of Medicine, 2016. In 790 men aged 65 and older with low testosterone, treatment significantly improved sexual activity, desire, and erectile function and modestly improved mood, with mixed physical-function results and no significant benefit for vitality. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Lincoff AM, Bhasin S, Nissen SE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). New England Journal of Medicine, 2023. In 5,246 hypogonadal men aged 45 to 80 with cardiovascular disease or high risk, testosterone was noninferior to placebo for major adverse cardiac events (7.0 percent versus 7.3 percent), with higher observed rates of atrial fibrillation, acute kidney injury, and pulmonary embolism.
